Pancreatic Cancer Research

ResearcherChiba UniversityActive in the last 2 years

Yousuke Nakai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7411-1385; OpenAlex author ID A5060049548, A5157624392. Sources: OpenAlex.

Their work

Papers
77 (first author 19, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
153
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers · 2013: 10 papers · 2014: 8 papers · 2015: 3 papers · 2016: 3 papers · 2017: 4 papers · 2018: 2 papers · 2019: 5 papers · 2020: 3 papers · 2021: 5 papers · 2022: 4 papers · 2023: 5 papers · 2024: 1 paper · 2025: 8 papers · 2026: 8 papers

Papers 50 of 77

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. Usefulness of an S-1 dosage formula for predicting adverse events in adjuvant chemotherapy for curatively resected pancreatic cancer: an exploratory analysis o… First author DOI 10.1007/s00535-026-02413-5↗
  3. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  4. Prognostic model for pancreatic cancer based on machine learning of routine slides and transcriptomic tumor analysis. Co-author DOI 10.1038/s41416-025-03308-7↗
  5. Clinical Practice Guidelines for Pancreatic Cancer 2025 From the Japan Pancreas Society: A Synopsis. Co-author DOI 10.1097/mpa.0000000000002600↗
  6. Association between Serum Human Satellite II RNA and miR-21-5p Levels and Time to Pancreatic Cancer Diagnosis in a Prospective Population-based Study. Co-author DOI 10.1097/mpa.0000000000002723↗
  7. Intraductal Papillary Mucinous Neoplasm and Pancreatic Cancer: Opportunity Knocks Twice. Co-author DOI 10.14309/ajg.0000000000003677↗
  8. From detection to ruling out in pancreatic cancer: a new perspective. First author DOI 10.21037/tgh-2026-0023↗
  9. Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT d… Co-author DOI 10.1007/s00535-024-02173-0↗
  10. Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database. Co-author DOI 10.1007/s00535-025-02253-9↗
  11. Relationship of Intrapancreatic Fat Deposition With Pancreatic Cancer Differs According to Carcinoma Types. Co-author DOI 10.1053/j.gastro.2025.04.032↗
  12. Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel: A Multicenter Retrospective Study. First author DOI 10.1097/mpa.0000000000002411↗
  13. Risk factors for pancreatic cancer in individuals with intraductal papillary mucinous neoplasms and no high-risk stigmata during up to 5 years of surveillance:… Co-author DOI 10.1136/gutjnl-2024-333259↗
  14. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
  15. Fatty Pancreas: Its Potential as a Risk Factor for Pancreatic Cancer and Clinical Implications. Last author DOI 10.3390/cancers17111765↗
  16. Endoscopic ultrasound-guided hepaticogastrostomy and endoscopic retrograde cholangiopancreatography-guided biliary drainage for distal malignant biliary obstru… First author DOI 10.5946/ce.2024.031↗
  17. The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection. First author DOI 10.1097/mpa.0000000000002291↗
  18. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression. Co-author DOI 10.1002/cjp2.323↗
  19. Early skeletal muscle mass decline is a prognostic factor in patients receiving gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer: a retrospec… Co-author DOI 10.1007/s00520-023-07659-w↗
  20. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  21. Combination of serum human satellite RNA and miR-21-5p levels as a biomarker for pancreatic cancer. Co-author DOI 10.1016/j.isci.2023.106021↗
  22. Gemcitabine plus nab-paclitaxel for pancreatic cancer and interstitial lung disease: A nationwide longitudinal study. Co-author DOI 10.1111/cas.15910↗
  23. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Co-author DOI 10.1002/jhbp.1085↗
  24. Targeting autophagy as a therapeutic strategy against pancreatic cancer. Co-author DOI 10.1007/s00535-022-01889-1↗
  25. KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer. Co-author DOI 10.1111/cas.15398↗
  26. Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment. Co-author DOI 10.3390/cancers14184351↗
  27. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. First author DOI 10.1007/s10637-020-00982-7↗
  28. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. First author DOI 10.1007/s10637-020-01022-0↗
  29. Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A… Co-author DOI 10.1016/j.clnu.2021.06.011↗
  30. Advanced Endoscopic Techniques for the Diagnosis of Pancreatic Cancer and Management of Biliary and GastricOutlet Obstruction. Co-author DOI 10.1016/j.soc.2021.06.005↗
  31. A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancr… First author DOI 10.5009/gnl19302↗
  32. EUS-guided fine-needle injection for pancreatic cancer: back to the future. Co-author DOI 10.1016/j.gie.2020.06.025↗
  33. Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer. Co-author DOI 10.1038/s41598-020-78320-3↗
  34. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. First author DOI 10.3390/diagnostics10080572↗
  35. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0691-9↗
  36. Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial. Co-author DOI 10.1016/j.gie.2019.06.032↗
  37. Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. Co-author DOI 10.1016/j.pan.2019.07.002↗
  38. Brain metastasis in pancreatic cancer: Two case reports. Co-author DOI 10.1097/md.0000000000014227↗
  39. Development of pancreatic cancer during observation for hepatocellular carcinoma: A retrospective cohort study. Co-author DOI 10.4103/sjg.sjg_56_19↗
  40. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic … Co-author DOI 10.1007/s12032-018-1158-8↗
  41. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001079↗
  42. Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case-cohort study. Co-author DOI 10.1007/s00330-017-4895-8↗
  43. Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. Co-author DOI 10.1038/bjc.2017.128↗
  44. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000000767↗
  45. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. First author DOI 10.1097/mpa.0000000000000889↗
  46. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Co-author DOI 10.1007/s10637-016-0369-0↗
  47. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. First author DOI 10.1016/j.ejca.2016.05.016↗
  48. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer. Co-author DOI 10.18632/oncotarget.11129↗
  49. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Co-author DOI 10.1007/s00432-014-1873-2↗
  50. Pancreatic cancer with malignant ascites: clinical features and outcomes. Co-author DOI 10.1097/mpa.0000000000000290↗

Closest collaborators

The 25 strongest of 153 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tsuyoshi Hamada · 34 shared papers, 2011–2026 · strength 3.48
  2. Mitsuhiro Fujishiro · 18 shared papers, 2011–2026 · strength 3.27
  3. Kazuhiko Koike · 48 shared papers, 2011–2024 · strength 2.71
  4. Hiroyuki Isayama · 49 shared papers, 2011–2025 · strength 2.58
  5. Naminatsu Takahara · 32 shared papers, 2011–2025 · strength 2.53
  6. Kazunaga Ishigaki · 19 shared papers, 2015–2026 · strength 2.39
  7. Tatsunori Suzuki · 11 shared papers, 2022–2026 · strength 1.94
  8. Hiroki Oyama · 9 shared papers, 2020–2026 · strength 1.80
  9. Kei Saito · 19 shared papers, 2014–2025 · strength 1.76
  10. Suguru Mizuno · 31 shared papers, 2011–2021 · strength 1.48
  11. Hirofumi Kogure · 34 shared papers, 2011–2021 · strength 1.47
  12. Hideaki Ijichi · 26 shared papers, 2012–2024 · strength 1.45
  13. Naoki Sasahira · 23 shared papers, 2011–2026 · strength 1.23
  14. Minoru Tada · 32 shared papers, 2011–2019 · strength 1.18
  15. Kiyoshi Hasegawa · 8 shared papers, 2016–2026 · strength 1.14
  16. Tsuyoshi Takeda · 9 shared papers, 2015–2026 · strength 1.06
  17. Koji Miyabayashi · 20 shared papers, 2012–2025 · strength 1.01
  18. Keisuke Yamamoto · 16 shared papers, 2011–2022 · strength 0.86
  19. Maxim S. Petrov · 3 shared papers, 2025–2026 · strength 0.83
  20. Yohei Masugi · 5 shared papers, 2022–2026 · strength 0.83
  21. Yosuke Inoue · 5 shared papers, 2022–2026 · strength 0.81
  22. Saburo Matsubara · 16 shared papers, 2011–2025 · strength 0.80
  23. Tomotaka Saito · 10 shared papers, 2014–2023 · strength 0.79
  24. Dai Mohri · 15 shared papers, 2011–2025 · strength 0.72
  25. Ryota Nakabayashi · 1 shared paper, 2026 · strength 0.63

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.